References
- Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899–910.
- Stuve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006;59:743–7.
- Kappos L, Radue EW, Comi G, et al. Switching from natalizumab to fingolimod: a randomized, placebo-controlled study in RRMS. Neurology 2015;85:29–39.
- Fox RJ, Cree BA, De Seze J, et al. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology 2014;82:1491–8.
- Sorensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 2012;18:143–52.
- Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2014;76:802–12.
- Basnyat P, Hagman S, Kolasa M, et al. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients. Mult Scler Relat Disord 2015;4:334–8.
- Borriello G, Prosperini L, Mancinelli C, et al. Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study. Eur J Neurol 2012;19:783–7.
- Tur C, Montalban X. Natalizumab: risk stratification of individual patients with multiple sclerosis. CNS Drugs 2014;28:641–8.
- Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol 2011;68:186–91.
- Rispens T, Vennegoor A, Wolbink GJ, et al. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped. Mult Scler 2012;18:899–901.
- Rossi S, Motta C, Studer V, et al. Treatment options to reduce disease activity after natalizumab: paradoxical effects of corticosteroids. CNS Neurosci Ther 2014;20:748–53.
- Rinaldi F, Seppi D, Calabrese M, et al. Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings. Mult Scler 2012;18:1640–3.
- Magraner MJ, Coret F, Navarre A, et al. Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study. J Neurol 2011;258:1805–11.
- Gueguen A, Roux P, Deschamps R, et al. Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis. J Neurol Neurosurg Psychiatry 2014;85:1038–40.
- Sloka JS, Stefanelli M. The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler 2005;11:425–32.
- Leussink VI, Jung S, Merschdorf U, et al. High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch Neurol 2001;58:91–7.
- Fine AJ, Sorbello A, Kortepeter C, Scarazzini L. Progressive multifocal leukoencephalopathy after natalizumab discontinuation. Ann Neurol 2014;75:108–15.
- Ferrè L, Moiola L, Sangalli F, et al. Recurrence of disease activity after repeated natalizumab withdrawals. Neurol Sci 2015;36:465–7.
- Antoniol C, Jilek S, Schluep M, et al. Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management? Neurology 2012;79:2258–64.
- O'Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011;76:1858–65.
- Rigau V, Mania A, Befort P, et al. Lethal multiple sclerosis relapse after natalizumab withdrawal. Neurology 2012;79:2214–6.
- Jokubaitis VG, Li V, Kalincik T, et al. Fingolimod after natalizumab and the risk of short-termrelapse. Neurology 2014;82:1204–11.
- Havla J, Kleiter I, Kümpfel T. Bridging, switching or drug holidays - how to treat a patient who stops natalizumab? Ther Clin Risk Manag 2013;9:361–9.